Table 2.
Univariate analysis of clinicopathological characteristics of patients with hepatoma in the MVI-positive group and MVI-negative group.
| Hepatoma, n = 62 | ||||
|---|---|---|---|---|
| MVI | ||||
| Negative (%) | Positive (%) | χ 2 | p value | |
| Age (years) | 0.204 | 0.652 | ||
| <60 | 8 (23.53%) | 8 (28.57%) | ||
| ≥60 | 26 (76.47%) | 20 (71.43%) | ||
| HBsAg | 0.150 | 0.698 | ||
| Positive | 24 (70.59%) | 21 (75.00%) | ||
| Negative | 10 (29.41%) | 7 (25.00%) | ||
| Tumor size (cm) | 10.620 | 0.001 | ||
| ≤3 | 25 (73.53%) | 9 (32.14%) | ||
| >3 | 9 (26.47%) | 19 (67.86%) | ||
| AFP (μg/mL) | 10.524 | 0.001 | ||
| <200 | 29 (85.29%) | 12 (42.86%) | ||
| ≥200 | 5 (14.71%) | 16 (57.14%) | ||
| Edmondson grade | 20.736 | <0.001 | ||
| I–II | 27 (79.41%) | 6 (21.43%) | ||
| III–IV | 7 (20.59%) | 22 (78.57%) | ||
| ALT (U/L) | 0.005 | 0.942 | ||
| <40 | 24 (68.28%) | 20 (71.43%) | ||
| ≥40 | 10 (31.72%) | 8 (28.57%) | ||
| AST (U/L) | 0.105 | 0.746 | ||
| <40 | 22 (64.71%) | 17 (60.71%) | ||
| ≥40 | 12 (35.29%) | 11 (39.29%) | ||
| NLR | 8.744 | 0.003 | ||
| <1.520 | 18 (52.94%) | 4 (14.29%) | ||
| ≥1.520 | 16 (47.06%) | 24 (85.71%) | ||
| PLR | 2.702 | 0.100 | ||
| <98 | 18 (52.94%) | 9 (32.14%) | ||
| ≥98 | 16 (47.06%) | 19 (67.86%) | ||
| APRI | 4.849 | 0.028 | ||
| <0.275 | 24 (70.59%) | 12 (42.86%) | ||
| ≥0.275 | 10 (29.41%) | 16 (57.14%) | ||
| CEA (μg/L) | 0.285 | 0.594 | ||
| <5 | 29 (85.29%) | 26 (92.86%) | ||
| ≥5 | 5 (14.71%) | 2 (7.14%) | ||
| CA19-9 (U/mL) | 0.007 | 0.932 | ||
| <37 | 29 (85.29%) | 25 (89.29%) | ||
| ≥37 | 5 (14.71%) | 3 (10.71%) | ||
| Number of tumors | 6.115 | 0.113 | ||
| Single | 29 (85.29%) | 16 (57.14%) | ||
| Multiple | 5 (14.71%) | 12 (42.86%) | ||